ArticleVeterinary research2026
Two-component system VraSR senses host defense peptide PMAP-36 to promote Streptococcus suis pathogenicity through regulating accD expression.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Streptococcus suis (S. suis) is an important zoonotic pathogen that causes severe infections in humans and animals worldwide. Upon infection, the host innate immune system produces host defense peptides (HDPs) to resist S. suis invasion. PMAP-36, a porcine-derived HDP, has been shown to fail to kill S. suis, suggesting that this pathogen has evolved strategies to evade PMAP-36-mediated immune defense. However, the exact mechanism by which S. suis responds to PMAP-36 remains unclear. Here we showed that PMAP-36 significantly enhanced S. suis adhesion, cytotoxicity, and virulence gene expression. The two-component system (TCS) VraSR was essential for PMAP-36 to promote S. suis pathogenicity. We demonstrated that PMAP-36 directly bound to the sensor kinase VraS. Further transcriptomic analysis revealed that VraSR sensed PMAP-36 to regulate fatty acid biosynthesis, in which a key gene accD expression was significantly downregulated in both PMAP-36-treated ΔvraS and ΔvraR mutant strains. Deletion of accD attenuates S. suis in vivo pathogenicity, including reduced bacterial loads, alleviated organ damage, and decreased inflammatory response. Additionally, VraSR-mediated accD expression was critical for S. suis-induced cytotoxicity and inflammatory response, as deletion of vraS or vraR fails to reduce inflammatory cytokines production due to sustained high accD expression. This study reveals VraSR-mediated virulence regulatory mechanism in response to HDP activation, which provides new insight into the development of novel strategies to combat S. suis infection.
Indexed as
Identifiers
42919420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.